Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.61 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.61 |
| ▸ | PDE5A | O76074 | 14/20 | 0.60 |
| ▸ | GUCY1A1 | Q02108 | 4/20 | 0.51 |
| ▸ | GUCY1B1 | Q02153 | 4/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL174830 | 0.91 | ADORA3 (0.63) | ADORA3KCNH2PDE5AGUCY1A1GUCY1B1 | |
| SCHEMBL7835258 | 0.90 | ADORA3 (0.65) | ADORA3KCNH2PDE5AGUCY1A1GUCY1B1 | |
| SCHEMBL27557251 | 0.90 | ADORA3 (0.60) | ADORA3KCNH2PDE5AGUCY1A1GUCY1B1 | |
| SCHEMBL174847 | 0.88 | ADORA3 (0.67) | ADORA3KCNH2PDE5AGUCY1A1GUCY1B1 | |
| SCHEMBL18212218 | 0.88 | ADORA3 (0.58) | ADORA3KCNH2PDE5AGUCY1A1GUCY1B1 | |
| SCHEMBL20682623 | 0.87 | ADORA3 (0.57) | ADORA3KCNH2PDE5AGUCY1A1GUCY1B1 | |
| SCHEMBL4939648 | 0.87 | ADORA3 (0.64) | ADORA3KCNH2PDE5AGUCY1A1GUCY1B1 | |
| Hydrochloric Acid SCHEMBL18496411 | 0.87 | ADORA3 (0.66) | ADORA3KCNH2PDE5AGUCY1A1GUCY1B1 | |
| Hydrochloric Acid SCHEMBL1930775 | 0.87 | ADORA3 (0.66) | ADORA3KCNH2PDE5AGUCY1A1GUCY1B1 | |
| SCHEMBL174909 | 0.86 | PDE5A (0.55) | ADORA3KCNH2PDE5AGUCY1A1GUCY1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2611802-B1 | BICYCLIC AZA-HETEROCYCLES AND THEIR USE | BAYER IP GMBH (DE) | 2016-02-24 | — | — | EP | disclosed |
| US-9096592-B2 | Bicyclic aza heterocycles, and use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-08-04 | — | — | US | disclosed |
| US-20140148433-A1 | BICYCLIC AZA HETEROCYCLES, AND USE THEREOF | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-05-29 | — | — | US | disclosed |
| EP-2611802-A1 | BICYCLIC AZA HETEROCYCLES, AND USE THEREOF | Bayer Intellectual Property GmbH (DE) | 2013-07-10 | — | — | EP | disclosed |
| WO-2012028647-A1 | BICYCLIC AZA HETEROCYCLES, AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-03-08 | — | — | WO | disclosed |
| EP-1339714-B1 | NOVEL SULFONAMIDE-SUBSTITUTED PYRAZOLOPYRIDINE DERIVATIVES | BAYER HEALTHCARE AG (DE) | 2006-10-18 | — | — | EP | disclosed |
| US-7115599-B2 | Sulfonamide-substituted pyrazolopyridine compounds | BAYER AKTIENGESELLSCHAFT (DE) | 2006-10-03 | — | — | US | disclosed |
| US-20040067937-A1 | Novel sulfonamide-substituted pyrazolopyridine derivatives | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2004-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140148433-A1 | BICYCLIC AZA HETEROCYCLES, AND USE THEREOF | AADAC, PAICS, TPMT | ADORA3 814/4885KCNH2 1555/4885PDE5A 152/4885 |
| US-20040067937-A1 | Novel sulfonamide-substituted pyrazolopyridine derivatives | GUCY1A2, GUCY1A1, GUCY1B2 | ADORA3 318/4885KCNH2 325/4885PDE5A 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.